Astrocytic processes at the synapse contribute to neurotransmission, but we understand little about their formation and differentiation. In this issue of Neuron, Yang et al. show that presynaptic input induces expression of the predominant glial transporter involved in glutamate clearance, and this induction involves the transcription factor kappa B-binding protein.
Astrocytes influence synaptic transmission in many ways. They secrete distinct factors that promote synaptogenesis, neurotransmitter release, and postsynaptic receptors (Barres, 2008) . In addition, they release so-called gliotransmitters in response to stimulation and contribute to the calcium waves that correlate with blood flow (Volterra and Meldolesi, 2005; Haydon and Carmignoto, 2006) . However, they also participate directly in synaptic transmission through the expression of high-affinity transporters for neurotransmitters.
In general, plasma membrane neurotransmitter transporters serve two distinct but related functions. First, they limit signaling by the released transmitter, either temporally in the case of neuromodulators such as monoamines or spatially in the case of glutamate. The excitatory amino acid transporters (EAATs) control spillover of glutamate from one synapse to another (Bergles et al., 1999) . Second, plasma membrane transporters serve to recycle the released transmitter for packaging and subsequent rerelease. In most cases, these transporters are expressed at the nerve terminal, where they are well positioned to serve both functions. In contrast, the major EAAT isoforms GLAST (human EAAT1) and GLT1 (human EAAT2) are expressed by glia and localize to astrocytic processes that reside at varying distances from the synapse. The EAATs thus require additional mechanisms to recycle their accumulated glutamate back to neurons through the so-called glutamine-glutamate cycle (Chaudhry et al., 2002b) as well as to position them near the synapse for clearance.
In light of their physiological role, the EAATs have attracted considerable attention in terms of their potential for regulation, and much of this work has focused on membrane trafficking (Robinson, 2006) . In the case of EAAT3, a neuronal isoform, stimulation of extrasynaptic receptors may cause insertion of more transporter, thus limiting spillover. Changes in the expression of EAATs may also contribute to disease. Loss of the most abundant isoform, GLT1, causes seizures and excitotoxicity (Tanaka et al., 1997) , and increased EAAT expression may protect against neural degeneration (Rothstein et al., 2005) . Interestingly, previous work in primary astrocyte culture has shown that neurons induce the expression of GLT1 (Gegelashvili et al., 1997; Swanson et al., 1997) .
In this issue of Neuron, Yang et al. characterize the mechanism by which neurons induce glial expression of GLT1 (Yang et al., 2009 ). Processes of cortical neurons plated in one chamber of a microfluidic device enter a second chamber containing astrocytes and induce local expression of GLT1. Contact is not absolutely required for this effect, but does correlate with higher levels of GLT1, and more processes correlate with a bigger increase in transporter expression. The authors then took advantage of BAC transgenic mice expressing GFP under control of GLT1 regulatory sequences (Regan et al., 2007) to show that the induction of GLT1 occurs at a transcriptional level. Tetrodotoxin can block the increase in GLT1 expression, suggesting that the effect depends on activity and may involve neurotransmitter release. Consistent with a role for released glutamate suggested by previous work (Duan et al., 1999) , glutamate receptor antagonists block the effect of neuronal processes on GLT1 expression, and metabotropic receptors appear particularly important, although AMPAtype receptors may contribute. The ability of antagonists for multiple glutamate receptors to each inhibit GLT1 induction is surprising and suggests that multiple signaling systems may be required for the effect.
The authors further used the BAC transgenic mice to understand the transcriptional regulation of GLT1 by neurons. In this case, they transfected cultures from the transgenic mice with a DsRed reporter under the control of GLT1 regulatory sequences, showing that these sequences confer appropriate expression of the reporter and induction by neurons. The analysis of serial deletions then identified a region required for both basal expression and neuronal induction. Focusing their attention on three highly conserved sequences within this region, the authors mutagenized each individually and found that only one (GGGTGGGTGT) dramatically affects expression. Although the promoter for GLT1 also contains multiple binding sites for the transcription factor nuclear factor kappa B (NFkB), mutation of these sites apparently had no effect.
In an elegant series of experiments, the authors extended the characterization in vivo. Adeno-associated viruses (AAV) encoding DsRed under the control of either the wild-type GLT1 promoter or the unresponsive mutant were injected into the ventricle of neonatal BAC transgenic mice, and expression of the reporter was assessed 3 weeks later. Although both constructs conferred expression in neurons, only the wild-type promoter conferred expression in astrocytes, confirming the importance of this sequence specifically for the induction of GLT1 in glia.
To identify the protein that interacts with this motif, the authors used a gel mobility shift assay. Nuclear extracts produce a specific band that increases from birth to 3 weeks, correlating with the transcriptional activation of GLT1 over this time. Mass spectrometry of the isolated protein identified it as the kappa B motif-binding phosphoprotein (KBBP), which is identical to the human heterogeneous nuclear ribonucleoprotein hnRNP K, a protein implicated in a number of cellular phenomena including RNA splicing as well as transcription (Bomsztyk et al., 2004) . Surprisingly, the kappa B (kB) enhancer element recognized by KBBP (GGGGACTTTCC) is not highly homologous to the sequence identified in GLT1. Nonetheless, the kB enhancer can compete out binding to the sequence in GLT1, and mutation of only the 5 0 guanosine residues conserved in both motifs suffices to eliminate GLT1 promoter activity, pointing to these residues as particularly important.
KBBP is widely expressed by neurons as well as astrocytes, but its expression in astrocytes correlates strongly with GLT1. Using the BAC transgenic mice, the authors showed that KBBP upregulates with GFP (and GLT1) in GFP + cells during early postnatal development. In culture, neurons also induce expression of KBBP by astrocytes. Further, AAV encoding antisense RNA for KBBP injected in vivo appear to knock down the expression of GFP as well as KBBP. Overexpression of KBBP in culture also upregulates GLT1, but only in the presence of neurons. Taken together, the results strongly suggest a role for KBBP in the transcriptional regulation of GLT1 by neurons.
To test a role for KBBP in neuronal regulation of GLT1 expression in vivo, Yang et al. used a series of lesion models. In the BAC transgenic mice, transection of the corticospinal tract causes a dramatic downregulation of KBBP, GLT1, and the GFP reporter below the site of the lesion. Unilateral administration of the neurotoxin ricin to peripheral nerve also downregulates KBBP and GLT1 in the ipsilateral ventral horn of the spinal cord, presumably due to the loss of axon collaterals within the cord. Finally, the authors mated the GLT1-GFP BAC transgenic mice to other transgenic mice expressing the G93A mutant of superoxide dismutase (SOD1) that have served as a model for human ALS and already been demonstrated to show a downregulation of GLT1 early in the course of disease (Howland et al., 2002) . The ventral horn of these double-transgenic animals indeed shows a downregulation of KBBP that strongly correlates with both GLT1 and the GFP reporter.
Taken together, the results indicate that KBBP participates in a signaling pathway through which presynaptic input activates the expression of GLT1 in glia. The elegant combination of BAC transgenic mice with a sophisticated culture system, reporter assay, biochemistry, and disease models has thus led to the identification of a novel element in signaling through a physiologically important pathway. Nonetheless, many questions remain. In addition to glutamate, membrane contact appears to play a role, and we do not know the factors responsible. Further, the mechanism by which glutamate receptor activation induces KBBP, and indeed the role of multiple glutamate receptors in this process, remains poorly understood. Since KBBP is widely expressed, it will be particularly interesting to determine why astrocytes specifically depend on neurons for the expression of KBBP, and whether this in turn involves transcriptional activation of KPPB or a posttranscriptional mechanism such as increased protein stability. It will also be very important to determine how the activation of GLT1 fits into the more general process of glial differentiation at the synapse.
The regulation of GLT1 expression by presynaptic input also raises important questions about cause and effect in neural degeneration. It is very clear that loss of GLT1 causes severe toxicity, and downregulation may occur in ALS. However, both previous work and the current report (Yang et al., 2009) suggest that the downregulation observed may reflect rather than cause neuronal loss. Indeed, downregulation in the absence of neural input might have less deleterious consequences than in the intact state, where the release of more glutamate has greater potential to produce toxicity. Neuronal regulation presumably serves to coordinate glutamate clearance with glutamate release. However, a defect in the signaling mechanism might trigger the degenerative process without a primary disorder of the neuron, and even secondary changes in EAAT expression may propagate the neuronal injury.
